Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026
Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Company Deals

Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam

Fineline Cube Jan 27, 2026
Company Deals

Insilico Medicine Partners with Qilu Pharma on AI Drug Development

Fineline Cube Jan 27, 2026
Company Deals

Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader

Fineline Cube Jan 27, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Fineline Cube Jan 28, 2026
Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Fineline Cube Jan 28, 2026
Company

WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business

Fineline Cube Mar 26, 2024

WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Jiangsu Hengrui’s Generic Version of Tepadina Approved for Transplantation Conditioning in China

Fineline Cube Mar 26, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC

Fineline Cube Mar 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...

Company

Sandoz Expands Antibiotics Production with New Austrian Factory

Fineline Cube Mar 25, 2024

Sandoz (OTCMKTS: SDZNY), a Swiss pharmaceutical company, has announced the opening of a new antibiotics...

Company Drug

Shanghai Institute’s Biosimilar Rituximab Approved by NMPA for Lymphoma Treatments

Fineline Cube Mar 25, 2024

Shanghai Institute of Biological Products Co., Ltd has announced that its biosimilar version of Roche/Genentech’s...

Company Drug

EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision

Fineline Cube Mar 25, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company

Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market

Fineline Cube Mar 25, 2024

Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of...

Company

Roche Invests EUR 90 Million in New Gene Therapy Center in Germany

Fineline Cube Mar 25, 2024

Swiss pharmaceutical giant Roche (SWX: RO) has inaugurated a new gene therapy development center in...

Company Drug

Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges

Fineline Cube Mar 25, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first...

Company Drug

FibroGen’s Roxadustat Approved in Macau for Chronic Kidney Disease-Related Anemia

Fineline Cube Mar 25, 2024

FibroGen Inc. (NASDAQ: FGEN), a biopharmaceutical company based in the US, has announced that it...

Policy / Regulatory

China’s Commerce Minister Meets with Global Pharma Leaders to Discuss Innovation Cooperation

Fineline Cube Mar 25, 2024

China’s Minister of Commerce, Wang Wentao, convened a high-level meeting with top executives from the...

Company Drug

Yifan Pharmaceutical’s F-627 Approved by European Commission for Marketing in EU

Fineline Cube Mar 25, 2024

Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that its subsidiary...

Company Deals

OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development

Fineline Cube Mar 25, 2024

OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in...

Company Drug

Grand Pharma Receives NMPA Approval for Global Phase III Study of RDC ITM-11 in GEP-NETs

Fineline Cube Mar 25, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Medical Device

Jenscare Scientific Completes Enrollment in Clinical Study for Mitral Valve Repair System

Fineline Cube Mar 25, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in...

Company Deals Digital

Zhejiang Dian Diagnostics Partners with Haihe Laboratory to Advance Hematology Diagnostics

Fineline Cube Mar 25, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a company based in China, has entered into...

Company Deals

Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments

Fineline Cube Mar 25, 2024

Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China,...

Company Deals Drug

Joincare Pharmaceuticals Secures Rights to Bayer’s Respiratory Drug in China

Fineline Cube Mar 25, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...

Company Deals

AriBio Expands Alzheimer’s Drug AR1001 Licensing Deal with Samjin to Include China

Fineline Cube Mar 25, 2024

AriBio Co., Ltd, a South Korea-based pharmaceutical company, has announced an expansion of its previous...

Company Deals

Sino Biological Partners with Rapid Novor to Market mAb Sequencing Services Across Asia

Fineline Cube Mar 22, 2024

Sino Biological Inc. (SHE: 301047), a leading supplier of reagents based in China, has announced...

Posts pagination

1 … 334 335 336 … 615

Recent updates

  • Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial
  • J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen
  • Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial
  • FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link
  • Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Company Drug

Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial

Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.